ORTHOLOGIC DOSES FOR AZX100 PHASE 1 DERMAL SCARRING

摘要

OrthoLogic Corp.(Nasdaq:OLGC),Tempe,Ariz.,has announced the initiation of dosing for its AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring.The clinical study is a first-in-man Phase 1,randomized,placebo controlled,dose-escalation,single center study in which the safety and tolerability of escalating doses of AZX100 will be evaluated in healthy adult male subjects.